Ischemic Stroke and ICU Care
Semin Neurol 28:645-656, Llinas, R, 2008
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic STroke
Stroke 47:581-641, Demaerschalk, B.M.,et al, 2016
Clinical Relevance of Microbleeds in Acute Stroke Thrombolysis
Neurol 87:1534-1541, Charidimou, A.,et al, 2016
Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013
The Types of Neurological Deficits Might Not Justify Withholding Treatment in Patients with Low Total National Institutes of Health Stroke Scale Scores
Stroke 43:782-786,625, Leira,E.C.,et al, 2012
Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated with Recombinant Tissue Plasminogen Activator
Stroke 43:2904-2909, Whiteley, W.N.,et al, 2012
Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine
Neurol 76:1780-1781, Tong, D., 2011
Established Treatments for Acute Ischaemic Stroke
Lancet 369:319-330, Khaja,A.M. &Grotta,J.C., 2007
Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations
Stroke 38:2612-2618, De Keyser,J.,et al, 2007
Reasons Why Few Patients With Acute Stroke Receive Tissue Plasminogen Activator
Arch Neurol 63:661-664, Bambauer,K.Z.,et al, 2006
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 36:916-921, Adams,H.,et al, 2005
Neurological Emergencies: Acute Stroke
JNNP 68:277-288, Davenport,R. & Dennis,M., 2000
Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 48:2031-2033, Tsivgoulis, G. & Safouris, A., 2017
Microbleed Status and 3-Month Outcome After Intravenous Thrombolysis in 717 Patients with Acute Ischemic Stroke
Stroke 46:2458-2463,2403, Turc, G.,et al, 2015
IV Thrombolysis in very severe and severe ischemic stroke
Neurol 85:2098-2106, Mazyam, M.V.,et al, 2015
Solitaire Flow Restoration Device Versus the Merci Retriever in Patients with Acute Ischaemic Stroke (SWIFT): a Randomised, Parallel-Group, Non-Inferiority Trial
Lancet 380:1241-1249,1208, Saver, J.L.,et al, 2012
Trevo Versus Merci Retrievers for Thrombectomy Revascularisation of Large Vessel Occlusions in Acute Ischaemic Stroke (TREVO 2): A Randomised Trial
Lancet 380:1231-1240,1208, Nogueira, R.G.,et al, 2012
An unusual cause of stroke and hypoxia
BMJ 342:c7200, Bell, S.L. & Eveson, D.J., 2011
Identifying Patients at High Risk for Poor Outcomes After Intra-Arterial Therapy for Acute Ischemic Stroke
Stroke 40:1780-1785, Hallevi,H.,et al, 2009
Usefulness of Checking Platelet Count Before Thrombolysis in Acute Ischemic Stroke
Stroke 38:1639-1640, Cucchiara,B.L.,et al, 2007
Prediction of Hemorrhagic Transformation After Recanalization Therapy Using T2*-Permeability Magnetic Resonance Imaging
Ann Neurol 62:170-176, Bang,O.Y.,et al, 2007
Bleeding Risk Analysis in Stroke Imaging Before ThromboLysis (BRASIL): Pooled Analysis of T2*-Weighted Magnetic Resonance Imaging Data From 570 Patients
Storke 38:2738-2744, Fiehler,J.,et al, 2007
Role of CT Angiography in Thrombolysis Decision-Making for Patients with Presumed Seizure at Stroke Onset
Stroke 37:915-917, Sylaja,P.N.,et al, 2006
Good Outcomes in Ischemic Stroke Patients treated With Intravenous Thrombolysis Despite Regressing Neurological Symptoms
Stroke 37:1332-1333, Baumann,C.R.,et al, 2006
Predicting Abnormal Coagulation in Ischemic Stroke: Reducing Delay in rt-PA Use
Neurol 67:1665-1667, Gottesman,R.F.,et al, 2006
Magnetic Resonance Imaging Criteria for Thrombolysis in Acute Cerebral Infarct
Stroke 36:388-397, Hjort, N., et al, 2005
Reasons for Exclusion From Thrombolytic Therapy Following Acute Ischemic Stroke
Neurol 64:719-720, Cocho,D., et al, 2005
Sonothrombolysis in Acute Ischemic Stroke for Patients Ineligible for rt-PA
Neurol 64:1052-1054, Eggers,J., et al, 2005
Safety and Efficacy of Mechanical Embolectomy in Acute Ischemic Stroke, Results of the MERCI Trial
Stroke 36:1432-1440, Smikth,W.D.,et al, 2005
Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke
Stroke 36:2497-2499, Smith,E.E.,et al, 2005
Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis With Tissue Plasminogen Activator in Very Old (=80 Years) Stroke Patients
Stroke 36:2421-2425, Berrouschot,J.,et al, 2005
Clinical Importance of Microbleeds in Patients Receiving IV Thrombolysis
Neurol 65:1175-1178, Kakuda,W.,et al, 2005
Hypoattenuation on CT Angiographic Source Images Predicts Risk of Intracerebral Hemorrhage and Outcome After Intra-Arterial Reperfusion Therapy
AJNR 26:1798-1803, Schwamm,L.,et al, 2005
Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke
Arch Neurol 61:346-350, Katzan,I.L.,et al, 2004
Are There Time-Dependent Differences in Diffusion and Perfusion Within the First 6 Hours After Stroke Onset?
Stroke 35:2099, Fiehler,J.,et al, 2004
Multiple Cerebral Microbleeds:MRI Marker of a Diffuse Hemorrhage-Prone State
J Neuroimaging 14:54-57, Chalela,J.A.,et al, 2004
Early Major Ischemic Changes on Computed Tomography Should Preclude Use of Tissue Plaminogen Activator
Stroke 34:820-821,822, von Kummer,R., 2003
Early Major Ischemic Changes on Computed Tomography Should Not Preclude Use of Tissue Plasminogen Activator
Stroke 34:821-822,822, Lyden,P.,et al, 2003
Why Are Stroke Patients Excluded from TPA Therapy?
Neurol 56:1015-1020, Barber,P.A.,et al, 2001
Stroke Treatment with Tissue Plasminogen Activator in the Setting of Aortic Dissection
Neurol 54:1010, Fessler,A.J. & Alberts,M.J., 2000